New Brain Institute Introduces Groundbreaking Ketamine Treatment for Treatment-Resistant Depression

New Brain Institute, a leading facility dedicated to mental health treatment, is proud to introduce SPRAVATO™, an FDA-approved ketamine therapy for treatment-resistant depression (TRD) in adults. SPRAVATO™ is a nasal spray administered in the institute's state-of-the-art treatment center, providing hope to patients who have not found relief from traditional antidepressant medications.

New Brain Institute proudly announces the introduction of SPRAVATO™, a ketamine-based therapy, offering a novel approach to treating depression. This treatment is especially significant for patients who have not found relief with traditional antidepressants.

SPRAVATO™ is administered under strict medical supervision. The initial phase includes treatments twice a week for four weeks, followed by weekly sessions for one month. Depending on individual responses, the frequency may be adjusted to once every one or two weeks.

This ketamine treatment has demonstrated superior efficacy compared to traditional pharmaceuticals, positioning it as a promising solution for those struggling with depression. With minimal side effects, SPRAVATO™ is emerging as a game-changer in mental health care.

Each treatment session at the New Brain Institute involves extensive monitoring by healthcare professionals in a comfortable setting, ensuring patient safety and well-being. Patients are advised to avoid driving or operating machinery until the following day. The institute also provides various insurance options to make this transformative therapy more accessible.